Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Very timely responses and fast shipment
(2024, CNS Neuroscience & Therapeutics ) confirmed ARA-290 provided neuroprotective effects in a mouse MCAO (middle cerebral artery occlusion) model comparable to full-length EPO, significantly reducing neuronal apoptosis and inflammatory cytokines, confirmed to act via CR without stimulating erythropoiesis Blood-brain barrier (BBB) penetration confirmed in pre-clinical studies
Manufactured using solid-phase peptide synthesis (SPPS) and validated through HPLC and Mass Spectrometry, this peptide is designed for cellular signaling, metabolic pathway, and protein interaction research
The mechanism appears to involve both an anti-inflammatory effect on melanocytes and normalization of the barrier function
Consent and Patient Education Every patient signs a detailed informed consent before starting
